IDHIFA (enasidenib)

TherapyBristol Myers Squibb, Servier Pharmaceuticals

IDHIFA (enasidenib) by Bristol Myers Squibb and Servier is a targeted therapy for relapsed or refractory IDH2-mutant AML.

Approvals

Indications

Biomarkers

Mapped tests

Where this therapy is approved with a companion diagnostic

Each row represents a defined combination of indication, biomarker criteria, and IDHIFA. Select a testing pathway to see the eligible companion diagnostic tests.

Indication-specific approvals

Approvals where IDHIFA is tied to a specific indication and biomarker definition.

Indication	Biomarker criteria	Notes
Acute Myeloid Leukemia (AML) Heme · Leukemia	IDH2 R140Q, R140L, R140G, R140W, R172K, R172M, R172G, R172S, and R172W		View testing pathway →

Tumor-agnostic approvals

Approvals defined at the solid tumor level where biomarker criteria determine eligibility for IDHIFA.

No tumor-agnostic companion diagnostic approvals are currently mapped for this therapy.

Tests used in these approvals

These assays are identified in FDA labeling or sponsor materials as companion diagnostics or acceptable tests when considering IDHIFA for eligible patients.

Test

Abbott RealTime IDH2

Abbott Molecular, Inc.

Method

PCR

Specimen

Whole blood

1 approvalView test profile →

This view is scoped to IDHIFA (enasidenib). You can also see how it compares with other therapies and indications on the main Know Your Companions™ map.